Covid-19 vaccines aren’t making any money for Johnson & Johnson

Covid-19 vaccines aren’t making any money for Johnson & Johnson
Annalisa Merelli

For many Americans, Johnson & Johnson (J&J) these days is most closely associated with the pharmaceutical company’s Covid-19 vaccine, which has been recently suspended in the US as authorities investigate its risk of causing a rare blood clot syndrome. Out of over $22 billion in sales, Covid-19 vaccines accounted for $100 million—or just above 2%, the company announced today.